Sanofi K.K. (Headquarters: Shinjuku-ku, Tokyo; President and CEO: Toshihiko Iwaiya) has conducted the "Pediatric Atopic Dermatitis Treatment Landscape Survey" to understand parental awareness of the disease, current treatment practices, and perceptions regarding treatment options—including molecular-targeted therapies—among caregivers of children with atopic dermatitis from infancy through middle school. This survey targeted 471 parents of children with moderate to severe atopic dermatitis symptoms. In this survey, about 90% of parents expressed a desire for their child to reach key developmental milestones—such as entering daycare, starting school, or adolescence—in a stable condition with controlled symptoms. However, only about 30% of parents reported having consulted their doctor about intensifying treatment (e.g., changing or adding medication). Notably, another 30% said they wanted to consult but had not done so, highlighting a gap between awareness of the need for treatment review and actual engagement with healthcare providers. Atopic dermatitis is a condition in which symptoms and impacts on daily life can change significantly from infancy through school age. However, when symptoms temporarily stabilize, observation without intervention may continue, often delaying necessary treatment adjustments. Moreover, prolonged symptoms can lead both children and families to become accustomed to the condition, accepting it as “just the way it is,” even while suspecting better treatment options may exist. Recent years have seen significant advances in atopic dermatitis treatment, making long-term remission (maintaining a good condition for extended periods) an achievable goal. It is now understood that early, appropriate intervention in childhood can lead to better long-term outcomes. Therefore, it is crucial to reassess a child’s symptoms and treatment plan at key transition points—such as ages 3, 6, and 12—when life circumstances change significantly. Shared understa